Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Debridement & negative-pressure wound therapy · Vermont | Debridement & negative-pressure wound therapy · New York | |
|---|---|---|
| Surgeons, 2024 | 18 | 877 |
| Medicare fee-for-service cases | 1,868 | 165,137 |
| Growth since 2019 (Medicare FFS) | −6.3%/yr | −3.1%/yr |
| Forecast cases (Medicare FFS) | 3,090 in 2030 | 176,500 in 2030 |
| Forecast growth | +8.7%/yr to 2030 | +1.1%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 15.9 | 86.3 |
| Medicare Advantage share | 35% | 57% |
| Out of hospital | 33% (−4 pts since 2019) | 54% (−5 pts since 2019) |
| Cases per surgeon | 104 | 188 |
| Top 10 surgeons' share | 76% | 19% |
| Surgeons growing | 3 | 183 |
| New since the base year | 7 | 266 |
| Likely to stop billing it | 6 by 2026 | 185 by 2026 |
| Forecast miss, 1 year (procedure) | 3% | 3% |
| Company payments per surgeon | $83 | $1,155 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.